Abstract:

Background: Multidrug-resistant tuberculosis (MDR-TB) has become a major public health problem and obstacle to global TB control. MDR-TB is associated with higher case fatality rates, especially among HIV-infected patients, and is much more difficult and costlier to treat than drug susceptible TB. Namibia is the country with the fourth highest TB burden in the world. The incidence rate in 2015 was 651/100 000. Multidrug-resistant tuberculosis (MDR-TB) has become a major public health problem, especially in developing countries, where the MDR-TB burden is the highest. In Namibia, among the regions highly affected by MDR-TB, Ohangwena region is facing many challenges. A recent study has demonstrated that the magnitude of the problem by numbers, about 40 per cent of patients admitted to the Katutura State Hospital’s TB unit and 30 per cent of patients who commenced treatment at the Engela District Hospital in the Ohangwena Region are Angolan nationals.

Objectives: To determine geospatial Multidrug-resistant and extensively drug-resistant Tuberculosis Distribution in Angola and Namibia; To investigate the impact of geospatial distribution on Multidrug-resistant and extensively drug-resistant Tuberculosis. Methods: this is a retrospective cohort study that will be performed on all cases of Multidrug-resistant and extensively drug-resistant Tuberculosis with confirmed laboratory test in Engela District Hospital between January 2013 and December 2017. Geospatial data will be used to illustrate all hypotheses.

Conclusion: this study could be crucial on its genre to establish different gaps between Angolan and Namibian in the management of MDR-TB in Engela district hospital.

References:

[1].     Kolifarhood Goodarz, Khorasani-Zavareh Davoud, Salarilak Shaker, Shoghli Alireza, Khosravi Nasim. Spatial and non-spatial determinants of successful tuberculosis treatment outcomes: An implication of Geographical Information Systems in health policy-making in a developing country. 2015;5(3):221-30.

[2].     Lelamobile. Angolans Treated Free of Charge for TB and HIV. In: https://www.lelamobile.com/content/49464/Angolans-Treated-Free-of-Charge-for-TB-and-HIV/. 2015.

[3].     Liu, Y., Li, X., Wang, W., Li, Z., Hou, M., He, Y., Wu, W., Wang, H., Liang, H. and Guo, X., 2012. Investigation of space-time clusters and geospatial hot spots for the occurrence of tuberculosis in Beijing. The International Journal of Tuberculosis and Lung Disease, 16(4), pp.486-491.

[4].     Mavenyengwa RT, Shaduka E, Maposa I. Evaluation of the Xpert(R) MTB/RIF assay and microscopy for the diagnosis of Mycobacterium tuberculosis in Namibia. Infectious diseases of poverty 2017;6(1):13.

[5].     Migliori Giovanni Battista, Dheda Keertan, Centis Rosella, Mwaba Peter, Bates Matthew, O’Grady Justin, et al. Review of multidrug‐resistant and extensively drug‐resistant TB: global perspectives with a focus on sub‐Saharan Africa. 2010;15(9):1052-66.

[6].     Ministry of Health and Social Services (MOHSS). National Tuberculosis and Leprosy Programme Annual Report: 2015-2016. http://www.mhss.gov.na/files/downloads/ed6_NTLPAnnualReport_20170116_Formatted.pdf 2016.

[7].     Moonan Patrick K, Bayona Manuel, Quitugua Teresa N, Oppong Joseph, Dunbar Denise, Jost Kenneth C, et al. Using GIS technology to identify areas of tuberculosis transmission and incidence. International Journal of Health Geographics 2004;3:23.

[8].     New Era. Angolan TB patients flock to Namibia. In: https://www.newera.com.na/2014/04/07/angolan-tb-patients-flock-namibia/. 2014.

[9].     Patterson Benjamin, Morrow Carl D, Kohls Daniel, Deignan Caroline, Ginsburg Samuel, Wood Robin. Mapping sites of high TB transmission risk: Integrating the shared air and social behaviour of TB cases and adolescents in a South African township. 2017; 583:97-103.

[10]. Ricks Philip M, Mavhunga Farai, Modi Surbhi, Indongo Rosalia, Zezai Abbas, Lambert Lauren A, et al. Characteristics of multidrug-resistant tuberculosis in Namibia. 2012;12(1):385.

[11]. Sagwa EL, Ruswa N, Mavhunga F, Rennie T, Leufkens HG, Mantel-Teeuwisse AK. Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort. BMC pharmacology & toxicology 2015;16:36.

[12]. Sagwa EL, Ruswa N, Mavhunga F, Rennie T, Leufkens HG, Mantel-Teeuwisse AK. Adverse events and patients' perceived health-related quality of life at the end of multidrug-resistant tuberculosis treatment in Namibia. Patient preference and adherence 2016; 10:2369-77.

[13]. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB):2010 Global Report on Surveillance and Response. In: http://apps.who.int/iris/handle/10665/44286. 2010.

[14]. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. In: http://www.who.int/tb/challenges/mdr/programmatic_guidelines_for_mdrtb/en/. 2014.

[15]. Zignol Matteo, Hosseini Mehran S, Wright Abigail, Weezenbeek Catharina Lambregts–van, Nunn Paul, Watt Catherine J, et al. Global incidence of multidrug-resistant tuberculosis. 2006;194(4):479-85.

[16]. Zvavamwe Simbisayi, Ehlers Valerie J. Implementing a community-based tuberculosis programme in the Omaheke region of Namibia: nurses' perceived challenges. 2008;13(3):54-68.